Is Mounjaro approved for weight loss or only diabetes?

Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes management. The same molecule is approved as Zepbound specifically for chronic weight management in adults with BMI ≥30 (or ≥27 with a weight-related comorbidity). The active ingredient is identical; the brand name and approved indication differ.

How does tirzepatide compare to semaglutide for weight loss?

Head-to-head data from the SURMOUNT and STEP programs (indirect comparison) suggest tirzepatide produces greater mean weight loss at maximum doses (approximately 20-22% vs 15-17%). The SURPASS-2 trial directly compared tirzepatide to semaglutide 1 mg for diabetes, showing superior HbA1c and weight reduction with tirzepatide. A direct comparison at weight-management doses has not been published as of mid-2026.

What monitoring should older patients on GLP-1 therapy receive?

The HealthRX.com Medical Team recommends: body composition assessment (DEXA or BIA) at baseline and every 6 months, renal function panels quarterly for the first year, DEXA for bone density annually in patients over 65, and routine lipid and HbA1c panels. Grip strength testing can serve as a practical sarcopenia screen.

Can you stay on Mounjaro indefinitely?

Current evidence supports long-term use. The SURMOUNT-4 trial demonstrated maintained efficacy at 88 weeks with no new safety signals emerging with extended use. Tirzepatide does not appear to lose efficacy over time (no tachyphylaxis has been documented). The decision to continue is individualized based on ongoing benefit-risk assessment.

The Medical Takeaways from Whoopi Goldberg's GLP-1 Story

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for The Medical Takeaways from Whoopi Goldberg's GLP-1 Story Image: HealthRX.com clinical image

The Public Record

Whoopi Goldberg disclosed her use of Mounjaro on The View, making her one of the most prominent women over 60 to publicly confirm GLP-1 receptor agonist use for weight management. The disclosure was notable not for shock value but for its matter-of-fact tone. Goldberg discussed the medication as a practical tool, not a secret or a shortcut.

This public confirmation matters because daytime television reaches a demographic (women 45+) that pharmaceutical marketing often targets through clinical language. Goldberg's straightforward framing, speaking about the drug by name on network television, normalized GLP-1 use for a population that may feel stigma around weight-management medications.

What Is Tirzepatide and How Does It Work?

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist approved by the FDA for type 2 diabetes management, with weight-management indications under the brand name Zepbound. Unlike semaglutide (Ozempic, Wegovy), which acts on GLP-1 receptors alone, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors.

This dual mechanism produces several physiological effects:

Slowed gastric emptying, reducing meal volume and increasing satiety
Enhanced insulin secretion in response to food intake
Suppressed glucagon release during hyperglycemia
Central appetite suppression via hypothalamic signaling

The SURMOUNT-1 trial demonstrated mean weight reductions of 15% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) at 72 weeks in adults with obesity, published in the New England Journal of Medicine. These are population averages. Individual response varies considerably based on age, baseline metabolic status, and adherence.

GLP-1 Efficacy in Patients Over 60: What the Data Shows

Goldberg's age at disclosure (late 60s) raises a clinically relevant question: do GLP-1 medications work differently in older adults?

A subgroup analysis from the STEP trials (semaglutide) published in JAMA Network Open found that adults over 65 lost less total body weight percentage than younger participants, though the difference was modest (approximately 2-3 percentage points less). Tirzepatide-specific age-stratified data from SURMOUNT showed similar patterns.

The HealthRX.com Medical Team notes three age-related considerations:

Sarcopenia risk. Weight loss in older adults carries a higher proportion of lean mass loss. A study in The Lancet on body composition changes during GLP-1 therapy found that approximately 25-40% of weight lost consists of lean tissue. For patients over 60, this ratio demands attention. Resistance training and adequate protein intake (1.0-1.2 g/kg/day minimum) are not optional add-ons but clinical necessities during GLP-1 therapy in this population.

Bone density. Rapid weight loss at any age correlates with accelerated bone mineral density decline. The Endocrine Society recommends DEXA monitoring for patients over 65 who lose more than 5% body weight in 6 months, regardless of mechanism.

Cardiovascular benefit. The SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease. For older patients with elevated cardiovascular risk, this represents a benefit beyond weight reduction. Tirzepatide cardiovascular outcome data (SURPASS-CVOT) is pending full publication, though interim signals appear favorable.

Side-Effect Realities

Goldberg's willingness to discuss the medication publicly provides an opening for honest side-effect counseling. The clinical trial data for tirzepatide at therapeutic doses shows:

| Side Effect | Incidence (5-15 mg range) | |---|---| | Nausea | 12-31% | | Diarrhea | 12-23% | | Constipation | 6-11% | | Vomiting | 5-12% | | Injection-site reactions | 3-7% |

Most gastrointestinal effects are dose-dependent and attenuate over 4-8 weeks at each dose level. The standard titration schedule (starting at 2.5 mg, escalating every 4 weeks) exists specifically to mitigate these effects. Patients who tolerate slower titration (6-8 weeks per step) often report fewer GI symptoms while achieving comparable long-term weight outcomes, per FDA prescribing information.

The HealthRX.com Medical Team emphasizes: nausea is not a sign the drug is "working." It is a side effect to manage, not a feature to celebrate. Patients who cannot eat adequately due to persistent nausea should discuss dose adjustment rather than accepting malnutrition as progress.

At a glance

Confirmed medication: Mounjaro (tirzepatide), disclosed publicly on The View
Drug class: Dual GIP/GLP-1 receptor agonist
Clinical context: Efficacy in adults over 60 is well-established but slightly lower than in younger populations
Key concern for this demographic: Lean mass preservation requires active resistance training and high protein intake
GI side effects: Common but dose-dependent and typically transient with proper titration
Discontinuation reality: Weight regain of 50-70% of lost weight is typical within 12 months of stopping

The Discontinuation Question

One reality that celebrity GLP-1 disclosures rarely address: what happens when you stop. The SURMOUNT-4 extension study, published in JAMA, found that participants who discontinued tirzepatide after 36 weeks regained approximately two-thirds of lost weight over the subsequent year. Participants who continued the medication maintained their weight loss.

This is not a failure of willpower. GLP-1 receptor agonists modify appetite signaling, gastric motility, and central reward pathways. When the drug is withdrawn, these systems revert toward baseline. The CDC classifies obesity as a chronic disease, and chronic diseases typically require ongoing treatment.

For patients considering GLP-1 therapy based on public stories like Goldberg's, the HealthRX.com Medical Team recommends framing this medication as a long-term or indefinite intervention, similar to statins for hyperlipidemia or antihypertensives for blood pressure management. The question is not "how long until I can stop" but "what maintenance strategy works for my life."

Dose-Response Patterns: Not Everyone Needs Maximum Dose

Tirzepatide is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses. Clinical practice shows substantial individual variability in optimal maintenance dose. Some patients achieve target outcomes at 5 or 7.5 mg. Others require 15 mg.

The SURMOUNT data showed a clear dose-response relationship at the population level, but individual "responder" status matters more than dose for any given patient. A post-hoc analysis found that early response (weight loss in the first 12 weeks) predicted long-term outcomes more reliably than final dose achieved.

The clinical implication: if a patient reaches a satisfactory result at a moderate dose, escalation to maximum is not mandatory. This counters the assumption that more drug equals better results for every individual.

What Non-Celebrity Patients Should Take From This

Goldberg's public disclosure normalizes a medical decision. The HealthRX.com Medical Team identifies four practical lessons from this public record:

Age is not a contraindication. GLP-1 therapy is effective and generally safe for adults over 60, with appropriate monitoring for lean mass loss and bone health.
Openness reduces stigma. Patients who discuss their medication use with their care team (and, optionally, their social circle) tend to have better adherence and lower discontinuation rates.
Expectations matter. A 15-20% total body weight reduction is a strong clinical outcome. Patients expecting more dramatic results based on social media anecdotes may experience unnecessary disappointment.
This is medicine, not a hack. Tirzepatide requires medical supervision, regular lab monitoring (renal function, lipid panels, HbA1c where applicable), and lifestyle modifications to be used safely and effectively.

Frequently asked questions

›

References

Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48. https://jamanetwork.com/journals/jama/fullarticle/2812936
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity (SELECT). N Engl J Med. 2023;389:2221-2232. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
FDA Prescribing Information: Mounjaro (tirzepatide). https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
Obesity and Overweight Facts. Centers for Disease Control and Prevention. https://www.cdc.gov/obesity/adult-obesity-facts/index.html